SpringWorks Total Current Liabilities vs Common Stock Analysis

SWTX Stock  USD 38.91  2.61  7.19%   
SpringWorks Therapeutics financial indicator trend analysis is much more than just breaking down SpringWorks Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SpringWorks Therapeutics is a good investment. Please check the relationship between SpringWorks Therapeutics Total Current Liabilities and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Total Current Liabilities vs Common Stock

Total Current Liabilities vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SpringWorks Therapeutics Total Current Liabilities account and Common Stock. At this time, the significance of the direction appears to have very strong relationship.
The correlation between SpringWorks Therapeutics' Total Current Liabilities and Common Stock is 0.87. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock in the same time period over historical financial statements of SpringWorks Therapeutics, assuming nothing else is changed. The correlation between historical values of SpringWorks Therapeutics' Total Current Liabilities and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of SpringWorks Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Current Liabilities i.e., SpringWorks Therapeutics' Total Current Liabilities and Common Stock go up and down completely randomly.

Correlation Coefficient

0.87
Relationship DirectionPositive 
Relationship StrengthStrong

Total Current Liabilities

Total Current Liabilities is an item on SpringWorks Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of SpringWorks Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock

Most indicators from SpringWorks Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SpringWorks Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.At this time, SpringWorks Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 38.08 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 237.1 M in 2024.
 2021 2022 2023 2024 (projected)
Cost Of Revenue490K1.9M422K400.9K
Research Development101.7M146.1M150.5M158.0M

SpringWorks Therapeutics fundamental ratios Correlations

0.910.80.530.820.430.70.840.120.190.860.690.640.310.650.28-0.19-0.64-0.640.940.86-0.68-0.890.820.940.95
0.910.90.50.920.510.540.750.020.340.780.860.840.30.790.37-0.14-0.84-0.840.760.98-0.52-0.990.940.830.75
0.80.90.410.80.830.420.81-0.340.690.680.890.73-0.130.870.730.3-0.74-0.740.640.86-0.41-0.870.820.70.63
0.530.50.410.330.090.630.36-0.310.220.630.280.60.250.450.0-0.13-0.6-0.60.450.35-0.63-0.430.720.480.37
0.820.920.80.330.430.390.760.090.20.830.760.680.340.660.28-0.21-0.69-0.690.710.9-0.37-0.940.820.820.71
0.430.510.830.090.430.160.66-0.640.90.350.670.34-0.650.680.980.76-0.34-0.340.320.47-0.17-0.460.370.340.33
0.70.540.420.630.390.160.460.090.020.560.310.420.310.330.0-0.24-0.43-0.430.690.45-1.0-0.50.520.660.69
0.840.750.810.360.760.660.46-0.20.380.840.630.52-0.10.480.560.18-0.33-0.330.870.68-0.45-0.730.620.880.84
0.120.02-0.34-0.310.09-0.640.09-0.2-0.84-0.07-0.17-0.10.79-0.33-0.7-0.850.080.080.190.15-0.06-0.11-0.070.150.26
0.190.340.690.220.20.90.020.38-0.840.150.550.34-0.720.690.920.84-0.4-0.40.020.28-0.03-0.270.330.050.0
0.860.780.680.630.830.350.560.84-0.070.150.540.510.250.540.21-0.15-0.52-0.520.830.67-0.54-0.750.750.890.8
0.690.860.890.280.760.670.310.63-0.170.550.540.730.010.790.580.15-0.74-0.740.50.85-0.3-0.840.770.640.52
0.640.840.730.60.680.340.420.52-0.10.340.510.730.310.590.25-0.15-0.8-0.80.530.82-0.4-0.840.910.610.44
0.310.3-0.130.250.34-0.650.31-0.10.79-0.720.250.010.31-0.07-0.76-0.98-0.34-0.340.30.35-0.28-0.360.370.340.3
0.650.790.870.450.660.680.330.48-0.330.690.540.790.59-0.070.60.25-0.88-0.880.370.76-0.32-0.740.780.430.4
0.280.370.730.00.280.980.00.56-0.70.920.210.580.25-0.760.60.85-0.23-0.230.190.33-0.01-0.320.240.190.19
-0.19-0.140.3-0.13-0.210.76-0.240.18-0.850.84-0.150.15-0.15-0.980.250.850.150.15-0.23-0.20.210.21-0.19-0.25-0.23
-0.64-0.84-0.74-0.6-0.69-0.34-0.43-0.330.08-0.4-0.52-0.74-0.8-0.34-0.88-0.230.151.0-0.38-0.820.410.81-0.91-0.46-0.37
-0.64-0.84-0.74-0.6-0.69-0.34-0.43-0.330.08-0.4-0.52-0.74-0.8-0.34-0.88-0.230.151.0-0.38-0.820.410.81-0.91-0.46-0.37
0.940.760.640.450.710.320.690.870.190.020.830.50.530.30.370.19-0.23-0.38-0.380.72-0.67-0.760.660.960.98
0.860.980.860.350.90.470.450.680.150.280.670.850.820.350.760.33-0.2-0.82-0.820.72-0.43-0.990.890.780.72
-0.68-0.52-0.41-0.63-0.37-0.17-1.0-0.45-0.06-0.03-0.54-0.3-0.4-0.28-0.32-0.010.210.410.41-0.67-0.430.48-0.5-0.64-0.67
-0.89-0.99-0.87-0.43-0.94-0.46-0.5-0.73-0.11-0.27-0.75-0.84-0.84-0.36-0.74-0.320.210.810.81-0.76-0.990.48-0.92-0.83-0.74
0.820.940.820.720.820.370.520.62-0.070.330.750.770.910.370.780.24-0.19-0.91-0.910.660.89-0.5-0.920.740.61
0.940.830.70.480.820.340.660.880.150.050.890.640.610.340.430.19-0.25-0.46-0.460.960.78-0.64-0.830.740.94
0.950.750.630.370.710.330.690.840.260.00.80.520.440.30.40.19-0.23-0.37-0.370.980.72-0.67-0.740.610.94
Click cells to compare fundamentals

SpringWorks Therapeutics Account Relationship Matchups

SpringWorks Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets334.8M576.2M452.5M630.2M725.8M762.1M
Other Current Liab9.3M13.5M24.2M38.8M64.5M67.7M
Total Current Liabilities12.0M17.6M30.0M51.0M78.2M82.1M
Total Stockholder Equity322.1M557.1M422.4M(569.9M)626.2M657.5M
Accounts Payable2.7M1.4M3.4M8.0M7.4M7.8M
Cash327.7M147.1M104.0M67.5M176.1M184.9M
Other Assets1.7M2.6M3.3M3.2M3.7M2.2M
Other Current Assets3.7M9.8M18.8M7.5M12.7M13.3M
Total Liab12.8M19.1M30.1M72.1M99.6M104.5M
Property Plant Equipment795K3.0M4.2M18.3M16.4M14.7M
Net Tangible Assets322.1M557.1M422.4M558.2M641.9M336.2M
Property Plant And Equipment Net795K3.0M4.2M18.3M24.1M25.3M
Net Debt(327.7M)(144.4M)(102.7M)(62.2M)(169.0M)(177.4M)
Retained Earnings(73.0M)(118.6M)(292.5M)(569.9M)(895.0M)(850.3M)
Non Current Assets Total3.5M62.8M69.6M30.5M224.9M236.1M
Non Currrent Assets Other1.7M2.6M3.3M3.2M4.2M2.5M
Cash And Short Term Investments327.7M508.5M373.5M597.0M479.2M368.0M
Common Stock Shares Outstanding43.0M43.3M48.5M53.3M63.1M49.5M
Liabilities And Stockholders Equity334.8M576.2M452.5M(497.9M)725.8M762.1M
Non Current Liabilities Total789K1.5M129K21.0M21.4M13.9M
Other Stockholder Equity395.1M675.6M715.2M1.1B1.5B1.6B
Net Invested Capital322.1M557.1M422.4M558.2M626.2M386.6M
Long Term Investments976K57.2M62.1M9.0M185.3M194.6M
Property Plant And Equipment Gross795K1.1M5.2M19.5M26.7M28.1M
Total Current Assets331.4M513.4M382.9M599.8M500.9M374.9M
Accumulated Other Comprehensive Income(334.8M)41K(312K)(767K)1.2M1.3M
Net Working Capital319.4M495.8M352.9M548.7M422.7M344.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.